Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC restated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report released on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $220.00 target price on the specialty pharmaceutical company’s stock. JAZZ has been the subject of several other reports. Barclays reduced their price […]

Related Keywords

Canada ,Los Angeles ,California ,United States ,Blackrock ,Philipl Johnson ,Patricia Carr ,Insider Transactions At Jazz Pharmaceuticals ,Barclays ,News Ratings For Jazz Pharmaceuticals Daily ,Thompson Siegel Walmsley ,Analyst Recommendations For Jazz Pharmaceuticals ,Los Angeles Capital Management ,Jazz Pharmaceuticals Company Profile ,Needham Company ,Royal Bank ,Blackrock Inc ,Cantor Fitzgerald ,Institutional Investors Weigh In On Jazz Pharmaceuticals ,Securities Exchange Commission ,Capital Management ,Jazz Pharmaceuticals Trading Down ,Nasdaq ,Jazz Pharmaceuticals ,Free Report ,Moderate Buy ,Pharmaceuticals Trading Down ,Get Free Report ,Exchange Commission ,Angeles Capital Management ,Jazz Pharmaceuticals Daily ,